November 25, 2024 - RTI Surgical ("RTI"), a leading CDMO pushing the boundaries of innovation and tissue engineering to address patient needs in regenerative medicine, today announced the enrollment ...

The US Food and Drug Administration has approved Symvess, the first acellular tissue engineered vessel indicated ... The serious risks of Symvess include graft rupture, anastomotic failure and ...

RTI Surgical Announces First Patient Enrolled in Investigational Device Exemption (IDE) for Cortiva® Allograft Dermis in Breast Reconstruction RTI Surgical Mon, Nov 25, 2024, 7:00 AM 2 min read ...